康弘药业：收到药物临床试验批准通知书

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for the treatment of insomnia, marking a significant step in the development of this innovative drug [2] Group 1: Company Developments - The company announced that it has obtained the Clinical Trial Approval Notice for KHN707 tablets, which are a selective orexin receptor 2 (OX2R) antagonist and classified as a Class 1 innovative chemical drug [2] - KHN707 is developed independently by the company, indicating its commitment to innovation in the pharmaceutical sector [2] Group 2: Industry Context - The approval for clinical trials reflects the ongoing advancements in the pharmaceutical industry, particularly in the development of new treatments for insomnia [2] - The drug's classification as a Class 1 innovative drug highlights its potential significance in addressing unmet medical needs in sleep disorders [2]